# US 2013/0158060 A1 · 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158060 A1
- Document ID: US20130158060A1
- Status: Published application
- Kind: A1
- Application number: 13/527,942
- Filed: 2012-06-20
- Published: 2013-06-20
- Earliest claimed: 2006-03-01
- Assignees: Theravance, Inc.
- Inventors: Daniel D. Long; John R. Jacobsen; Lan Jiang
- Web page: https://patentgrep.com/patent/US20130158060A1

## CPC

- C07D 451/02: containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61K 31/46: 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/10: Laxatives
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 25/30: for treating abuse or dependence
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.

## Claims

### Claim at position 1

1-26. (canceled)

### Claim 27

A compound of the formula
or a pharmaceutically acceptable salt thereof.

### Claim 28 (depends on 27)

A pharmaceutical composition comprising the compound of claim 27 and a pharmaceutically-acceptable carrier.

### Claim 29 (depends on 27)

A method of treating opioid-induced bowel dysfunction or post-operative ileus in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically-acceptable carrier and the compound of claim 27.

### Claim 30 (depends on 27)

A method of reducing a gastrointestinal side effect associated with use of an opioid agent in a mammal, the method comprising administering to the mammal an opioid agent and the compound of claim 27.

### Claim 31 (depends on 30)

The method of claim 30 wherein the opioid agent is selected from morphine, pethidine, codeine, dihydrocodeine, oxycontin, oxycodone, hydrocodone, sufentanil, fentanyl, remifentanil, buprenorphine, methadone, and heroin.

### Claim 32 (depends on 31)

The method of claim 31 wherein the opioid agent is morphine.

### Claim 33 (depends on 31)

The method of claim 31 wherein the opioid agent is oxycodone or hydrocodone.

### Claim 34 (depends on 27)

A method of enhancing motility of the gastrointestinal tract in a mammal, the method comprising administering to the mammal a pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a compound of claim 27.

### Claim 35

A pharmaceutically acceptable salt of a compound of the formula

### Claim 36 (depends on 35)

A pharmaceutical composition comprising the compound of claim 35 and a pharmaceutically-acceptable carrier.

### Claim 37 (depends on 35)

A method of treating opioid-induced bowel dysfunction or post-operative ileus in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically-acceptable carrier and the compound of claim 35.

### Claim 38 (depends on 35)

A method of reducing a gastrointestinal side effect associated with use of an opioid agent in a mammal, the method comprising administering to the mammal an opioid agent and the compound of claim 35.

### Claim 39 (depends on 38)

The method of claim 38 wherein the opioid agent is selected from morphine, pethidine, codeine, dihydrocodeine, oxycontin, oxycodone, hydrocodone, sufentanil, fentanyl, remifentanil, buprenorphine, methadone, and heroin.

### Claim 40 (depends on 39)

The method of claim 39 wherein the opioid agent is morphine.

### Claim 41 (depends on 39)

The method of claim 39 wherein the opioid agent is oxycodone or hydrocodone.

### Claim 42 (depends on 35)

A method of enhancing motility of the gastrointestinal tract in a mammal, the method comprising administering to the mammal a pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a compound of claim 35.

### Claim 43

A compound of the formula

### Claim 44 (depends on 43)

A pharmaceutical composition comprising the compound of claim 43 and a pharmaceutically-acceptable carrier.

### Claim 45 (depends on 43)

A method of treating opioid-induced bowel dysfunction or post-operative ileus in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically-acceptable carrier and the compound of claim 43.

### Claim 46 (depends on 43)

A method of reducing a gastrointestinal side effect associated with use of an opioid agent in a mammal, the method comprising administering to the mammal an opioid agent and the compound of claim 43.

### Claim 47 (depends on 46)

The method of claim 46 wherein the opioid agent is selected from morphine, pethidine, codeine, dihydrocodeine, oxycontin, oxycodone, hydrocodone, sufentanil, fentanyl, remifentanil, buprenorphine, methadone, and heroin.
